Eglumetad

Eglumetad
Clinical data
Other names	Eglumegad; LY354740
ATC code	none;
Identifiers
	IUPAC name (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;
CAS Number	176199-48-7 ;
PubChem CID	213056;
IUPHAR/BPS	1393;
ChemSpider	184747 ;
UNII	ONU5A67T2S;
CompTox Dashboard (EPA)	DTXSID40170094 ;
Chemical and physical data
Formula	C8H11NO4
Molar mass	185.179 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@H]1[C@]2([H])CC[C@](C(O)=O)(N)[C@@]21[H];
	InChI InChI=1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1 ; Key:VTAARTQTOOYTES-RGDLXGNYSA-N ;
	(what is this?) (verify)

Eglumetad (INN; also known as eglumegad) is a research drug developed by Eli Lilly and Company, which is being investigated for its potential in the treatment of anxiety^[1] and drug addiction.^[2] It is a glutamate derived compound and its mode of action implies a novel mechanism.^[3]

^ Pilc A (January 2003). "LY-354740 (Eli Lilly)". IDrugs. 6 (1): 66–71. PMID 12789623.
^ Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, Pilc A (December 1999). "Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models". Neuropharmacology. 38 (12): 1831–9. doi:10.1016/S0028-3908(99)00066-0. PMID 10608278. S2CID 23149472.
^ Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (February 1997). "Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties". J. Med. Chem. 40 (4): 528–37. doi:10.1021/jm9606756. PMID 9046344.

[pmid12789623-1] Pilc A (January 2003). "LY-354740 (Eli Lilly)". IDrugs. 6 (1): 66–71. PMID 12789623.

[pmid10608278-2] Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, Pilc A (December 1999). "Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models". Neuropharmacology. 38 (12): 1831–9. doi:10.1016/S0028-3908(99)00066-0. PMID 10608278. S2CID 23149472.

[pmid9046344-3] Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (February 1997). "Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties". J. Med. Chem. 40 (4): 528–37. doi:10.1021/jm9606756. PMID 9046344.

[1]

[2]

[3]